Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Cost of Revenue (2021 - 2025)

HeartSciences (HSCS) has disclosed Cost of Revenue for 5 consecutive years, with $1008.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 98.96% year-over-year to $1008.0, compared with a TTM value of $197940.0 through Oct 2025, down 1.39%, and an annual FY2025 reading of $1880.0, down 69.08% over the prior year.
  • Cost of Revenue was $1008.0 for Q4 2025 at HeartSciences, up from $760.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $99091.0 in Q3 2024 and bottomed at $760.0 in Q1 2023.
  • Average Cost of Revenue over 5 years is $19518.8, with a median of $1520.0 recorded in 2023.
  • The sharpest move saw Cost of Revenue soared 6286.91% in 2024, then tumbled 99.23% in 2025.
  • Year by year, Cost of Revenue stood at $5756.0 in 2021, then crashed by 64.63% to $2036.0 in 2022, then decreased by 25.34% to $1520.0 in 2023, then skyrocketed by 6286.91% to $97081.0 in 2024, then crashed by 98.96% to $1008.0 in 2025.
  • Business Quant data shows Cost of Revenue for HSCS at $1008.0 in Q4 2025, $760.0 in Q3 2025, and $97081.0 in Q4 2024.